Codex DNA Total Liabilities

The latest total liabilities for DNAY is $21M as of September 2024. That compares with $59M in the prior-year period — down 64.4% year over year. Investors often review this figure alongside Codex DNA's historical trend and sector peers before judging valuation or financial health.

Over the past year, DNAY's total liabilities moved from $59M to $21M — a 64.4% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Codex DNA's operating scale or balance-sheet position.

A total liabilities figure of $21M for DNAY is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting DNAY's total liabilities ($21M), review year-over-year change from $59M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Codex DNA's total liabilities against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.